Vaccines for Covid-19 are poised to become a big business. Their potential to generate staggering revenues has already added billions of dollars to the market value of drugmakers like Pfizer and Moderna.
That promise is also attracting scrutiny in Washington.
Rising prescription-drug costs are one of the few issues where Democrats and Republicans can find common ground. That’s a risk for drug companies, and one that weighs on their stock prices.
The Covid-19 pandemic muted the drug-pricing discussion in Washington. But signs that the issue could be revived emerged this past week just as Pfizer (ticker: PFE) and AstraZeneca (AZN) unveiled promising data on their vaccines.